To Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning
Phase 3
Withdrawn
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic Syndrome
- Registration Number
- NCT00226512
- Lead Sponsor
- Hadassah Medical Organization
- Brief Summary
Multi-institutional randomized phase III trial of a non-myeloablative preparative regimen with fludarabine and busulfex with or without anti-lymphocyte antibodies (monoclonal humanized Campath-1H administered s.c. or polyclonal rabbit anti-T lymphocyte antibodies (ATG), combined with low dose and short course cyclosporine A (CSA) and methotrexate (MTX) as the sole agent for prevention of graft-vs-host disease (GVHD) for patients with acute myelogenous leukemia or myelodysplastic syndrome undergoing allogeneic stem cell transplantation from an HLA compatible donor.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- 203
Inclusion Criteria
- Confirmed diagnosis of AML or MDS, with no lower or upper age limit:
- a) Induction failure
- b) First or subsequent remission
- c) Untreated first relapse
- Patients must have an HLA compatible donor willing and capable of donating peripheral blood stem cells (first choice) or bone marrow progenitor cells using conventional techniques and blood lymphocytes if indicated (HLA compatible defined as 5/6 or 6/6 matched related or 10/10 molecular matched unrelated donor (A,B,C,DR,DRB1).
Exclusion Criteria
- Donor contraindication (HIV seropositive confirmed by Western Blot, Hepatitis B antigenemia).
- Evidence of bone marrow disease.
- Unable to donate bone marrow or peripheral blood due to concurrent medical condition.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method To determine the efficacy of s.c. Campath-1H or ATG in decreasing the incidence and severity of acute and chronic GVHD in patients with AML and MDS treated with non-myeloablative stem cell transplantation.
- Secondary Outcome Measures
Name Time Method Investigate the role of different conditioning regimens on: Infection, engraftment relapse rate and disease free survival.
Trial Locations
- Locations (1)
Hadassah Medical Organization
🇮🇱Jerusalem, Israel